Brind.

MarketBeat Compares Financials and Analyst Ratings for Hims & Hers Health and Cencora

1 report, 1 independent Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

MarketBeat published a comparison of Hims & Hers Health and Cencora, examining metrics such as profitability, risk, and valuation. The report noted that Cencora has higher gross revenue and earnings per share than Hims & Hers Health. Furthermore, Hims & Hers Health trades at a lower price-to-earnings ratio than Cencora.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The comparison highlights differences in financial profiles and market risk between the two healthcare companies, which are competitors in the sector. Hims & Hers Health has a beta of 2.44, indicating higher volatility compared to Cencora’s beta of 0.58.

From themarketsdaily.com

Who's involved

  • MarketBeatProvided the financial analysis and analyst recommendations
  • Hims & Hers HealthAmerican telehealth company whose financial metrics were compared
  • CencoraUS drug wholesale company whose financial metrics were compared

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Hims & Hers HealthSpeculative

    Investors might adjust investment based on the reported lower price-to-earnings ratio and higher stock volatility.

  • CencoraSpeculative

    Investors might adjust investment based on the reported higher revenue and earnings compared to its competitor.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped